David Hung

David Hung

Algemeen Directeur bij NUVATION BIO INC.

Vermogen: 289 M $ op 31-05-2026

68 jaar
Health Technology
Finance
Consumer Services

Profiel

David T.
Hung
was the founder of Medivation LLC (California), founded in 1995, serving as President, Chief Executive Officer & Director from 2003 to 2016.
Dr. Hung was the founder of Medivation, Inc., founded in 2003, serving as President, Chief Executive Officer & Director from 2003 to 2016.
Dr. Hung is the founder of Nuvation Bio Operating Co., Inc., founded in 2018, serving as President, Chief Executive Officer & Director since 2018.
Dr. Hung is the founder of Nuvation Bio, Inc., founded in 2018, serving as Chairman, President & Chief Executive Officer since 2024.
Dr. Hung is also the founder of Repharmation, Inc...
Current positions include Chairman at T-Therapeutics Ltd., Independent Director at NovoCure Ltd. since 2018, Director at Establishment Labs SA since 2016, and Director at Auransa, Inc. Former positions include President & Chief Executive Officer at Orion Acquisition Corp.
II; President, Chief Executive Officer & Director at Pro-Duct Health, Inc. from 1999 to 2001; President, Chief Executive Officer & Director at Medivation Neurology LLC from 2011 to 2016; Chief Executive Officer & Director at Sio Gene Therapies, Inc. from 2017 to 2018; Chief Executive Officer & Director at Axovant Sciences, Inc. from 2017 to 2018; Director at Agilvax, Inc.; Director at Solbec Pharmaceuticals Ltd.; Independent Director at Opexa Therapeutics, Inc. from 2010 to 2011; Director at NKT Therapeutics, Inc.; Director at Roivant Sciences GmbH; Independent Director at Establishment Labs Holdings, Inc. from 2016 to 2021; Independent Director at ARYA Sciences Acquisition Corp.
from 2018 to 2021; VP-Lead Discovery, Development & New Projects at Chiron Corp.
from 1996 to 1998; Consultant at Cytyc Health Corp.
in 2003.
Education includes undergraduate degree from Harvard College and doctorate from UCSF School of Medicine.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
25-03-2026 59.281.054 ( 17,02% ) 283 M $ 31-05-2026
25-03-2026 1.000.000 ( 6,37% ) 5 M $ 31-05-2026
03-06-2026 32.075 ( 0,03% ) 546 558 $ 31-05-2026

Actieve functies van David Hung

BedrijvenFunctieBegin
NOVOCURE LIMITED Directeur/Bestuurslid 31-05-2018
NUVATION BIO INC. Algemeen Directeur 20-03-2018
Oprichter 01-01-2018
Directeur/Bestuurslid -
Repharmation, Inc.
Oprichter -
Directeur/Bestuurslid 01-02-2016

Eerdere bekende functies van David Hung

BedrijvenFunctieEinde
ESTABLISHMENT LABS HOLDINGS INC. Directeur/Bestuurslid 11-02-2021
ARYA SCIENCES ACQUISITION CORP. Directeur/Bestuurslid 01-01-2021
SIO GENE THERAPIES INC. Algemeen Directeur 12-02-2018
░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
Ervaring van David Hung in detail bekijken

Opleiding van David Hung

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

54

Eerstegraads connecties

24

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit24

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Cytyc Health Corp.

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Repharmation, Inc.

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. David Hung